Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00332241 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 65 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Apr 2008 to Apr 1, 2008
    • Start date: Jun 2006 to Jun 1, 2006
    • Study title revised
    v65
  2. Lead sponsor: Bristol-Myers Squibb to Otsuka Pharmaceutical Development & Commercialization, Inc.v64
  3. Publications: details revised at 1 of 4 entriesv63
  4. Re-verified, no change to tracked fieldsv62
  5. Results first posted: Jul 23, 2009
    • Primary endpoint revised
    • Secondary endpoints: 4 to 7
    v61
Show 45 earlier versionsHide 45 earlier versions
  1. Enrollment target: 164 to 98v60
  2. 2 versions Re-verified since Jun 27, 2008, no change to tracked fieldsv58-v59
  3. Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 200 to confirmed 164
    v57
  4. Enrollment target: 100 to 200
    • Study sites: 11 to 9
    • Primary and study completion dates: Jun 2008 to Apr 2008
    v56
  5. Study sites: 16 to 11v55
  6. Re-verified, no change to tracked fieldsv54
  7. Study sites: 19 to 16v53
  8. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 20 to 19
    • Primary completion date: Jun 2008
    • Study completion date: Oct 2008 to Jun 2008
    v52
  9. Site contacts updated at 2 of 20 sitesv51
  10. Site contacts updated at 4 of 20 sitesv50
  11. 2 versions Re-verified since Jan 8, 2008, no change to tracked fieldsv48-v49
  12. Interventions: Aripiprazole (Drug) to Aripiprazole (Drug), Placebo (Drug)
    • Study arms: 0 to 2
    v47
  13. Site details revised at 1 of 20 sitesv46
  14. Re-verified, no change to tracked fieldsv45
  15. Study completion date: Oct 2008v44
  16. 11 versions Re-verified since Jul 31, 2007, no change to tracked fieldsv33-v43
  17. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 20 of 20 sites
    v32
  18. Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (20)
    v31
  19. 2 versions Re-verified since May 30, 2007, no change to tracked fieldsv29-v30
  20. Secondary endpoints: details revised at 4 of 4 entriesv28
  21. Study sites revised (20)v27
  22. Re-verified, no change to tracked fieldsv26
  23. Study sites revised (20)v25
  24. Study sites revised (20)v24
  25. Study sites revised (20)v23
  26. Study sites: 22 to 20v22
  27. Site details revised at 4 of 22 sitesv21
  28. Eligibility criteria shortened, about 15 wordsv20
  29. Study sites: 21 to 22v19
  30. Study sites: 20 to 21v18
  31. Site details revised at 2 of 20 sitesv17
  32. Site details revised at 1 of 20 sitesv16
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
Trial Details
NCT Number NCT00332241
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators: Otsuka America Pharmaceutical
Conditions
(from sponsor)		 Autistic Disorder
Related terms Autistic Disorder, Problem Behavior
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov